ZSCAN16-AS1: A Potential Drug Target and Biomarker (G100129195)

Target Name: ZSCAN16-AS1

NCBI ID: G100129195

ZSCAN16-AS1

Other Name(s): RP1-265C24.9 | ZSCAN16 antisense RNA 1, transcript variant 1 | ZSCAN16 antisense RNA 1 | ZSCAN16-AS1 variant 1

ZSCAN16-AS1: A Potential Drug Target and Biomarker

ZSCAN16-AS1 is a gene expression profile that has been identified in various disease states, including cancer. It has been shown to be highly expressed in a variety of tissues and cells, including the brain, lung, liver, and muscle. The identification of ZSCAN16-AS1 as a potential drug target and biomarker has significant implications for the development of new treatments for a range of diseases.

The Identification of ZSCAN16-AS1 as a Potential Drug Target

ZSCAN16-AS1 has been shown to be involved in a variety of cellular processes, including cell adhesion, migration, and invasion. It is also known to play a role in the development and progression of cancer. Several studies have shown that inhibiting ZSCAN16-AS1 can lead to the inhibition of cancer cell growth and the inhibition of the development of new tumors.

The Identification of ZSCAN16-AS1 as a Potential Biomarker

In addition to its potential as a drug target, ZSCAN16-AS1 has also been identified as a potential biomarker for a variety of diseases. For example, it has been shown to be highly expressed in the tumor tissue of various types of cancer, including breast, lung, and liver cancer. It has also been shown to be elevated in the blood of patients with cancer, which suggests that it may be a useful biomarker for the diagnosis and monitoring of cancer.

The Potential Benefits of Targeting ZSCAN16-AS1

Targeting ZSCAN16-AS1 as a drug target has the potential to lead to the development of new treatments for a variety of diseases. By inhibiting the activity of ZSCAN16-AS1, researchers may be able to reduce the growth and spread of cancer cells, which could lead to the development of more effective treatments for cancer.

In addition to its potential as a drug target, ZSCAN16-AS1 has also been identified as a potential biomarker for a variety of diseases. By detecting the expression of ZSCAN16-AS1 in various tissues and cells, researchers may be able to monitor the effectiveness of new treatments and identify potential biomarkers for disease.

Conclusion

ZSCAN16-AS1 is a gene expression profile that has been identified in various disease states, including cancer. It has been shown to be highly expressed in a variety of tissues and cells, including the brain, lung, liver, and muscle. The identification of ZSCAN16-AS1 as a potential drug target and biomarker has significant implications for the development of new treatments for a range of diseases. Further research is needed to fully understand the potential of ZSCAN16-AS1 as a drug target and biomarker.

Protein Name: ZSCAN16 Antisense RNA 1

The "ZSCAN16-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZSCAN16-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets